Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Boris Kovatchev
University of Virginia, Department: Psychiatry
Should you be removed from our database? Contact us at [email protected]. Read more below.
TypeZero LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Boris Kovatchev and Marc Breton own equity in TypeZero, a Delaware Limited Liability Company. TypeZero has licensed technologies from UVa related to closed-loop control of diabetes, including background technology for the Diabetes Assistant (DiAs) platform and the algorithms comprising the Unified Safety System (USS Virginia). These algorithms will be used in this R01.
These research activities have the potential to validate the utility of this platform and these algorithms and thus could alter the financial interests of TypeZero.
Closed-Loop Control Modalities in Type 1 Diabetes: Efficacy and System Acceptance
Closed-Loop Control Modalities in Type 1 Diabetes: Efficacy and System Acceptance The future of the artificial pancreas (AP) as optimal treatment for type 1 diabetes is within reach. To fulfil their promise to all, AP systems need to prove their efficacy i rigorous clinical trials with outcomes targeting key parameters of glucose control-hemoglobin A1c and risk for hypoglycemia. We therefore propose to deploy the novel technologies we have developed in the past several years, in a long-term study aiming to establish that optimal balance between AP system complexity and benefits to the patient is achieved by a system that automatically takes over a person's blood glucose control in the evening and then stabilizes and 'resets' blood glucose levels to normal by the morning. Such an approach follows the natural wake-sleep circadian cycle, takes advantage of overnight steady-state glucose levels, and is proven with our current technology.
Filed on March 01, 2015.
Tell us what you know about Boris Kovatchev's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Boris Kovatchev filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Boris Kovatchev | University of Virginia | Conflict of Interest | TypeZero Technologies, LLC | Value cannot be readily determined |
| Boris Kovatchev | University of Virginia | Conflict of Interest | TypeZero Technologies, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.